For each citation that was shared on social media (LinkedIn, Facebook, or Twitter) with the “@GenScript” tag, the author will be rewarded with a $10 Amazon gift card or 2,000 GS points.

In vivo HSC gene therapy for SARS-CoV2 infection using a decoy receptor

Hum Gene Ther. 2022-01; 
Hongjie Wang, Chang Li, Adebimpe Obadan, Hannah Frizzell, Tien-Ying Hsiang, Sucheol Gil, Audrey Germond, Connie Fountain, Audrey Baldessari, Steve Roffler, Hans-Peter Kiem, Deborah Fuller, Andre Lieber
Products/Services Used Details Operation
Recombinant Antibody Expression … sACE2-Ig ELISA. Recombinant SARS-CoV2 S1 protein (Genscript, cat# Z03501) was diluted to 1.5 μg/mL in phosphate-buffered saline and immobilized on 96-well enzyme-linked … Get A Quote


While SARS-CoV2 vaccines have shown an unprecedented success, the ongoing emergence of new variants and necessity to adjust vaccines justifies the development of alternative prophylaxis and therapy approaches. Hematopoietic stem cell (HSC) gene therapy using a secreted CoV2 decoy receptor protein (sACE2-Ig) would involve a one-time intervention resulting in long-term protection against airway infection, viremia, and extrapulmonary symptoms. We recently developed a technically simple and portable in vivo hematopoietic HSC transduction approach that involves HSC mobilization from the bone marrow into the peripheral blood stream and the intravenous injection of an integrating, helper-dependent adenovirus (HDAd5/35... More